In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Drs. Desai and Abu Rous discuss trial data from Flaura2 and Mariposa as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss the Crown study data as presented at ASCO 2024, and its implications in treating ALK+ NSCLC.
Drs. Desai and Abu Rous discuss the data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.
Drs. Desai and Abu Rous discuss trial date from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss using tarlatamab in treating extensive stage small cell lung cancer.
Drs. Patel, Sheth, and Weiss discuss emerging data and advances in thyroid cancer treatment.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in incurable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in recurrent/metastatic HPV positive head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV positive head and neck cancer.
Dr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss whether a patient's location can affect the treatments they can access and their overall prognosis.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss how to navigate treatment and Covid vaccination.
Dr. Sridevi Rajeeve discusses current FDA approved bispecific antibodies and ones coming from clinical trials.
Dr. Alankrita Taneja examines data from the CESAR trial, and discusses curative strategies for Smoldering Multiple Myeloma.
Dr. Sridevi Rajeeve discusses possible side effects from bispecific antibodies, and how to manage them.
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
Dr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC
Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.
Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.
Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Joshua Reuss examines data on neoadjuvant targeted therapy.
Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC.
Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).
Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.
Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.
Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.
Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.
Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.
Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease.
Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC.
Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment.
Dr. Rana McKay discusses why it's crucial to get a prostate cancer screening.
डॉ. अलंकृता तनेजा ट्रांसजेंडर मरीजों में देखे जाने वाले सामान्य परामर्श मुद्दों पर चर्चा करती हैं, और सही मॉनिटरिंग का महत्व बताती हैं।(Dr. Alankrita Taneja discusses common consultation issues seen in transgender patients, and the importance of proper monitoring.)
डॉ. अलंकृता तनेजा टेस्टोस्टेरोन थेरेपी और इसके साथ आने वाले जोखिमों पर चर्चा करती हैं, जिसमें द्वितीय एरिथ्रोसाइटोसिस भी शामिल है।(Dr. Alankrita Taneja discusses testosterone therapy and the risks that come with it, including secondary erythrocytosis.)
डॉ. अलंकृता तनेजा सिकल सेल रोग वाले लोगों के लिए उपचार विकल्पों की जांच करती हैं, जो जेंडर अफर्मिंग हार्मोन थेरेपी के अधीन हैं।(Dr. Alankrita Taneja examines the treatment options for people with Sickle Cell Disease who are undergoing gender affirming hormone therapy.)
डॉ. अलंकृता तनेजा एस्ट्रोजन थेरेपी और इसके संभावित दुष्प्रभावों की जांच करती हैं।(Dr. Alankrita Taneja examines estrogen therapy and its potential side effects.)
डॉ. अलंकृता तनेजा भारत में ट्रांसजेंडर लोगों के संबंधित शब्दावली और सामाजिक मुद्दों का एक संक्षिप्त विवरण देती है।(Dr. Alankrita Taneja gives a brief description of terminology and social issues surrounding transgender people in India.)
Dr. Vernon Sondak makes the argument that neoadjuvant therapy leads to a better immune response in patients with melanoma.
Dr. Vernon Sondak discusses the pros and cons of neoadjuvant therapy, or receiving treatment before surgery.
Dr. Vernon Sondak discusses the pros and cons of adjuvant therapy, or receiving treatment after surgery.
Dr. Meredith McKean discusses recent findings in adjuvant therapy for patients with stage 3 or 4 melanoma.
Dr. Vernon Sondak discusses current patient treatment standards, including using immune therapy before targeted therapy in unresectable stage 4 disease.
© 2020-2025 Ivy Podcast Discovery LLC
